Breath Test to Detect Esophageal, Gastric Cancers May Be Feasible

Share this content:
Breath Test to Detect Esophageal, Gastric Cancers May Be Feasible
Breath Test to Detect Esophageal, Gastric Cancers May Be Feasible

WEDNESDAY, Feb. 1, 2017 (HealthDay News) -- A breath test to detect esophageal and gastric cancers shows promise, according to a study presented at the European Cancer Congress, held from Jan. 27 to 30 in Amsterdam.

The test measures five chemicals in the breath. The researchers found it to be 85 percent accurate in detecting esophageal and gastric cancers in more than 300 patients.

In an effort to assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers, the investigators say that they are planning a larger trial over the next three years in patients who are being given an endoscopy for gastrointestinal symptoms but have not yet been diagnosed with cancer.

"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies," study author Sheraz Markar, M.D., from Imperial College London, said in a European Cancer Congress news release. "In the longer term this could also mean earlier diagnosis and treatment, and better survival."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »